Subscribe to the DPJ Weekly Brief newsletter: Subscribe
LEIPZIG, Germany - The Chemical, Biological, Radiation and Nuclear (CBRN) detection business of Bruker Daltonik GmbH in Leipzig, Germany today announces that it has received a Euro 3.5 million ($ 4.7 million) contract award for its RAID(TM)-S chemical agent detectors from a major navy on the Indian Subcontinent. Bruker Daltonics is expected to deliver and integrate its RAID-S detectors in the second half of 2007 and the first half of 2008 in order to provide real-time chemical agent detection capabilities on board navy vessels of various es. The contract also includes a multiyear maintenance contract. Mr. Sebastian Meyer-Plath, Vice President for CBRN Detection at Bruker Daltonics, commented: "We are very pleased with our selection. This contract is more evidence that the RAID-S has arguably become the most advanced shipboard chemical agent detector in the world today with detection performance and interference rejection second-to-none. This contract extends our RAID-S users list by another major blue water navy." About Bruker BioSciences (NASDAQ: BRKR)Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc., Bruker AXS Inc. and Bruker Optics Inc. For more information, please visit www.bruker-biosciences.com For more information, contact:Bruker BioSciences CorporationMichael Willett, Investor Relations OfficerPhone: (978) 663-3660 ext. 1411Email: Michael.Willett@Bruker.comCautionary Statement Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the companies' reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the companies' products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors areentified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2006, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K and the joint proxy statement/prospectus filed in connection with the merger. We disclaim any intent or obligation to update these forward-looking statements.